Physician profile
John Supance
NPI 1194751727
$223.82
in general payments reported to CMS, 2019-2025
6 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118 · 2020: $14.82 · 2021: $57.70 · 2022: $32.95.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $64.88 | 2021-2022 | |
| Optinose US, INC. | $55.61 | 2019 | |
| Stryker Corporation | $40.22 | 2019 | |
| Depuy Synthes Sales INC. | $25.77 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $22.52 | 2019 | |
| Medtronic USA, INC. | $14.82 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Supance listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.